Floatz logo

Peg-Ifn

Cirrhosis Of Liver

Louis Stokes VA Medical CenterUNKNOWNN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

134 Active assets in the Cirrhosis Of Liver cohort.

Asset / SponsorPhaseRating
Veruprevir
AbbVie
Phase 3A
Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide)
General Hospital of Shenyang Military Region
Phase 4BBB
Tolvaptan
Institute of Liver and Biliary Sciences, India
Phase 4BBB
Ribavirin
Peking University People's Hospital
Phase 4BBB
Cholyl-Lysl-Fluorescein
Norgine
Phase 3BBB

View all 50 →

Same molecule, other indications

Peg-Ifn is also rated in:

fibrotic liver diseaseDormant
BB
Indicative · Phase 4
68 / 100
View asset →
chronic hepatitis C virus infectionDormant
D
Indicative · N/A
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →